[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100346956":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":21,"studyPopulation":22,"armGroups":23,"interventions":29,"overallOfficials":37,"centralContacts":42,"locations":53,"responsibleParty":73,"collaborators":17,"id":77,"slug":17,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":17,"enrollmentInfo":85,"targetDuration":17,"studyType":88,"phases":17,"briefSummary":89,"conditions":90,"keywords":17,"overallStatus":56,"whyStopped":17,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Tata Memorial Hospital","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Gene expression changes","The primary outcome measured will be gene expression changes during surgical resection. Messenger ribonucleic acid (mRNA) transcripts will be quantitated and their levels evaluated during different time-points of surgical resection, using high throughput omics technologies (Next generation sequencing, nanostring ncounter, qRT-PCR array).","The study aims to evaluate gene expression changes during surgical resection, which lasts for 30-90 minutes on an average. Thus, we have not planned a clinical follow-up or collection of data for the patients post sampling during surgical resection.",[14],{"measure":15,"description":16,"timeFrame":12},"Immunohistochemistry for other markers","The secondary outcome measured will be protein expression changes during surgical resection. Protein levels will be quantitated, and their levels evaluated, during different time-points of surgical resection. Transcripts found to be de-regulated or changed at different time-points of surgical resection will be evaluated using IHC at protein level. We will also use high throughput omics technologies (SILAC, ITRAQ) for characterising these changes at protein levels.",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"OTHER","PROSPECTIVE","Three tumor samples will be obtained after the patient is under anaesthesia,\n\n1. Prior to starting surgery (Sample A)\n2. The middle intra-operative sample, which will be collected when half the tumour has been devascularized (i.e., somewhere midway during the surgery). (Sample B)\n3. A third post excision (anoxic sample C). These tumour tissue samples will be stored as snap frozen, in RNA later and as paraffin sections.\n\nTo understand the effects induced by acute hypoxia that sets in during surgery in breast cancer. To study this, clinical samples (Tumor biopsies) will be obtained during and stored for future genomic and proteonomic evaluations.","Women diagnosed with breast cancer at outpatient clinic",[24],{"label":25,"type":17,"description":26,"interventionNames":27},"Intra-operative tumour tissue biopsies","Intra-operative tumour tissue biopsies will be collected for all patients",[28],"Procedure: Intra-operative Tumor Tissue Biopsy",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"PROCEDURE","Intra-operative Tumor Tissue Biopsy","The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.",[25],[36],"Breast cancer surgery",[38],{"name":39,"affiliation":40,"role":41},"Rajendra Badwe","Director, tata Memorial Centre","PRINCIPAL_INVESTIGATOR",[43,49],{"name":44,"role":45,"phone":46,"phoneExt":47,"email":48},"Shalaka Joshi, MS, MCh","CONTACT","9869089803","4265","drjoshishalaka@gmail.com",{"name":50,"role":45,"phone":51,"phoneExt":17,"email":52},"Rohini A Hawaldar","09820432613","rwhawaldar@gmail.com",[54],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Tata Memorial Center","RECRUITING","Mumbai","Maharashtra","400012","India","IN",{"type":63,"coordinates":64},"Point",[65,66],72.88261,19.07283,{"lat":66,"lon":65},[69,71],{"name":44,"role":45,"phone":70,"phoneExt":47,"email":48},"22241608601",{"name":72,"role":45,"phone":51,"phoneExt":17,"email":52},"Rohini A Hawaldar, BSc",{"type":41,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":76,"oldNameTitle":17,"oldOrganization":17},"Dr Rajendra A. Badwe","Director, Tata Memorial Centre and Professor, Department of Surgical Oncology","Tata Memorial Centre","100346956",false,"NCT03797482","A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer","Hypoxia","Inclusion Criteria:\n\n1. Clinically diagnosis of breast cancer (by FNAC or Biopsy)\n2. Not received any chemotherapy or surgical intervention except core biopsy.\n3. Planed for Breast cancer surgery\n4. Willing to give consent for the study\n\nExclusion Criteria:\n\n1. Clinically diagnosis of Metastatic breast cancer\n2. Received any anticancer therapy","FEMALE","18 Years",{"count":86,"type":87},500,"ESTIMATED","OBSERVATIONAL","To understand the effects induced by acute hypoxia that sets in during surgery in breast cancer. To study this, clinical samples (Tumor biopsies) will be obtained during the surgery after partial devascularisation (sample B) and stored for future genomic and proteonomic evaluations.",[91],"Breast Cancer Female","2025-09-03",{"date":94,"type":95},"2025-09-10","ACTUAL",{"date":97,"type":95},"2017-11-27",{"date":99,"type":87},"2025-11-30",{"name":5,"class":6},1]